Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
Latest From Pricing Debate
Draft order wants "comprehensive review" to find regulations that that "unnecessarily increases expenses" for patients, researchers, and manufacturers.
Draft version of order signals a focus on insurance benefit design, accelerating drug approvals and de-regulation.
Document that appears to be fueling upcoming executive order includes ideas for relaxing FDA standards for complex generic approval, which may be one way of creating pressure to lower prices.
Trump administration's drug pricing action plan considers withdrawing guidance and whole or parts of rules that biopharma has opposed.
US agency is seeking feedback from interested stakeholders about administrative steps it can take to better promote generic competition; July 18 meeting will involve only presentations from the public.
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
Celgene, Express Scripts, and Aetna discuss need for shared accountability, data sharing and value assessment at DIA meeting.
The high cost of basal insulins in the US has drawn a fair amount of scrutiny recently, placing increased pressure on new longer acting insulins to demonstrate superior cost-efficacy compared to standard of care Lantus to gain preferential formulary placement. This has become significantly more difficult with the US launch of Lilly's biosimilar, Basaglar.
Allergan CEO Brent Saunders, speaking at the BIO International Convention on June 19, said the biopharma industry needs to improve its image before its defenders in Congress bow to public pressure on drug pricing concerns.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.